3 Battleground Biotech Stocks I Would Avoid at All Costs
Arena Pharmaceuticals, Amarin Corp., and Keryx Biopharmaceuticals each have relatively new drugs that once captured the market's imagination. With their real world success in doubt, though, investors might be wise to jump ship now.
Bull Or Bear? Biotech's Post-Earnings Buys and Sells
The breakdown on which companies' numbers are easiest to swallow.
The 3 Most Disappointing Drug Launches of All Time
Treatments with huge promise don't always pan out the way you'd expect.